An interventional study of Chewing gum in Cognitive Dysfunction, sponsored by Inha University Hospital. Recruiting at 4 sites in Korea, Republic of. Open to participants aged 60 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-24.
Sponsored by Inha University Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Cognitive Dysfunction with a site in Korea, Republic of — 17 open to participants now, 24 under way, 5 of them phase 3. Cognitive Dysfunction · Korea, Republic of.
Among the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, this one is the 29th largest by planned enrollment of the 57 interventional ones that give a count, is one of 9 that started in 2022, is one of 37 with no phase, reaches primary completion later than 3 of the 23 other live ones, and was the 53rd registered.
3,878 studies on the registry are indexed under Cognitive Dysfunction; 1,120 are open to participants now.
Browse Cognitive Dysfunction studies →17 of the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Korea, Republic of, United States, Japan and 1 more country
Ages 55–85
Deepsonbio · Sites in Korea, Republic of
Ages 55–90
NeuroBiogen Co., Ltd · Sites in Korea, Republic of
Ages 50–85
Bristol-Myers Squibb · Sites in Korea, Republic of, United States, Argentina and 16 more countries
Ages 60–85
Hoffmann-La Roche · Sites in Korea, Republic of, United States, Argentina and 12 more countries
Ages 50–90
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 753 Cognitive Dysfunction studies recruiting now, 363 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 261 take healthy volunteers.
This study: 60 Years to 79 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 9 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 94 is above the median of 64 across 2,799 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 94 across the 57 interventional studies, 163 across the 17 observational. Of the 34 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 74 have an industry lead sponsor. The 10 most frequent:
Inha University Hospital is the lead sponsor of 37 studies on the registry; 8 are open to participants now.
Inha University Hospital has 6 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
10 of the studies in Cognitive Dysfunction with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT07239310DeepsonbioNeuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease | 2026-12 |
| NCT07334366Pusan National University Yangsan HospitalBroccoli Sprout Extract for Cognitive Function | 2026-12-30 |
| NCT07011680Pusan National University Yangsan HospitalPhospholipid-rich Dairy Extract for Cognitive Function | 2026-12-30 |
| NCT06786676Amyloid Solution IncA Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of AS-S603 in Healthy Participants | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to investigate whether the improvement or maintenance of cognitive function is superior to the control group when gum chewing is performed in elderly people with subjective cognitive decline or mild cognitive impairment.
The intervention group chew one unscented gum provided by the study for 12 weeks. Using KakaoTalk, the coordinator sends a chewing gum alarm.
The participants are instructed to masticate a gum for 20 minutes every day, alternately for 10 minutes on the right side and 10 minutes on the left side.
After chewing gum, they perform masticatory muscle stretching and tongue exercises. After they finish chewing the gum, he or she reports completion by posting an authentication photo in the KakaoTalk chat room.
The research coordinator checks the certification on a weekly basis and sends a separate phone call to encourage participants who do not chew gum more than twice a week.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention group chew one unscented gum provided by the study for 12 weeks. The participants are instructed to masticate a gum for 20 minutes every day, alternately for 10 minutes on the right side and 10 minutes on the left side. After chewing gum, they perform masticatory muscle stretching and tongue exercises. After they finish chewing the gum, he or she reports completion by posting a proof photo in the KakaoTalk chat room.
Other: Chewing gum
The control group does not participate in chewing gum.
chewing gum everyday for 12 weeks. Alternate chewing for 10 minutes on the right and 10 minutes on the left.
Change of cognition
Repeatable Battery for the Assessment of Neuropsychological Status (range 40-160). Higher scores indicate better performance.
Time frame: Change from Baseline at 12 weeks
Change of global cognition
Korean Mini-Mental State Examination-2 (range, 0-30). Higher scores indicate better performance.
Time frame: Change from Baseline at 12 weeks
Change of function
Clinical Dementia Rating scale-Sum of Boxes (range 0-18). Higher scores indicate worse performance.
Time frame: Change from Baseline at 12 weeks
Change of depression
Geriatric Depression Scale-15 items (range 0-15). Higher scores indicate worse mood.
Time frame: Change from Baseline at 12 weeks
Change of activities of daily living
Bayer Activities of Daily Living (range 1-10). Higher scores indicate worse performance.
Time frame: Change from Baseline at 12 weeks
Change of quality of life
Quality of life-Alzheimer's disease (range 0-52). Higher scores indicate better performance.
Time frame: Change from Baseline at 12 weeks
Change of cortical thickness and brain network function
brain MRI (3D-T1 weighted images and resting state functional MRI)
Time frame: Change from Baseline at 12 weeks
Plan to share: Yes — The data that support the findings of this study will be available from the principal investigator upon reasonable request.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Data will be available for 2 years since March 2025.
Access criteria: Reasonable request
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for Dec 2023, 13 months after the start.
Of 1,450 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 13 months is below that.
Counting every sponsor, half of 1,519 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Inha University Hospital